Deseret Mutual Benefit Administrators boosted its holdings in shares of Humana Inc. (NYSE:HUM – Free Report) by 18.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 303 shares of the insurance provider’s stock after purchasing an additional 47 shares during the period. Deseret Mutual Benefit Administrators’ holdings in Humana were worth $113,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of HUM. CarsonAllaria Wealth Management Ltd. increased its position in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the period. Private Wealth Management Group LLC acquired a new position in shares of Humana in the fourth quarter valued at approximately $32,000. Hantz Financial Services Inc. acquired a new position in shares of Humana in the second quarter valued at approximately $35,000. Family Firm Inc. purchased a new stake in shares of Humana during the second quarter worth approximately $37,000. Finally, Riverview Trust Co acquired a new stake in shares of Humana during the second quarter worth $44,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
HUM has been the subject of a number of analyst reports. Robert W. Baird initiated coverage on shares of Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective for the company. TD Cowen increased their price target on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Oppenheimer lifted their price objective on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Baird R W raised Humana to a “hold” rating in a research note on Thursday, May 30th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Monday, August 19th. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $396.35.
Humana Price Performance
HUM traded down $6.71 during midday trading on Thursday, reaching $364.69. 114,636 shares of the company’s stock were exchanged, compared to its average volume of 1,622,012. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $530.54. The stock has a market capitalization of $43.95 billion, a PE ratio of 23.13, a P/E/G ratio of 3.16 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The business’s 50-day moving average price is $367.95 and its 200 day moving average price is $347.21.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $8.94 EPS. As a group, equities analysts anticipate that Humana Inc. will post 16.14 EPS for the current fiscal year.
Humana Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Monday, September 30th. Humana’s payout ratio is currently 22.04%.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More
- Five stocks we like better than Humana
- How to buy stock: A step-by-step guide for beginners
- Recession or Not, These 3 Stocks Are Winners
- Health Care Stocks Explained: Why You Might Want to Invest
- Why NVIDIA Is More of a Screaming Buy Than Ever
- Compound Interest and Why It Matters When Investing
- Don’t Miss These 3 Stocks Set to Defy Expectations in September
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.